Angiogenesis conference set for September
A conference examining the progress made in the field of
angiogenesis inhibition,organised by SRI, will take place 29-30
September in Cambridge, Massachusetts.
Pharmagene says profitability is a realistic objective
Pharmagene has reported a near-doubling in turnover in the first
half of this year, on the back of strong growth in its drug
discovery services division.
Dharmacon gets US RNAi patent
Dharmacon has been awarded a US Patent (No 6,590,093) which covers
its proprietary 2'-ACE chemistry for the production of synthetic
Takeda strikes deals to boost pipeline
Takeda signs two new research collaborations in the areas of
Alzheimer's disease and antibody-based drugs, in a move to bolster
its product pipeline.
GPC says anti-MHC antibody is nearing clinic
GPC reports progress with its anti-MHC class II antibody, with
potential in a range of haematological malignancies, and says it
now has sufficient quantities to start a clinical trials programme.
Pfizer pulls out of Phytopharm collaboration
Botanical drug specialist Phytopharm suffered a setback yesterday
when Pfizer withdrew from a collaboration to develop P57, a drug
for obesity and metabolic syndrome.
Gene silencing promise sparks IP rush
The battle to amass intellectual property in the hot area of RNA
interference (RNAi) continues to gain pace, with one of the key
players in the category, Alnylam Pharmaceuticals, licensing patents
from the UK's Cambridge Research...
siRNA library to benefit Abbott, and others
Dharmacon and Abbott Laboratories are to develop a
short-interfering RNA (siRNA) library covering 4,000 genes to help
identify potential drug targets.
Argonaut exits HPLC business
Argonaut sells its HPLC business to Grace Vydac as it refocuses on
supplying consumables for companies working on drug discovery.
Reports reduced losses in first half.
New skin cancer gene located
Cancer Research UK scientists have found the location of a new gene
on chromosome 1 which pre-disposes people to skin cancer.
GSK signs up for ACLARA's eTag system
GSK is the latest company to sign a license for ACLARA Biosciences'
eTag Assay System, used in gene expression profiling studies.
Speeding up the search for natural medicines
German researchers have developed a technique to speed up the
discovery of medicinal plant compounds, using a combination of
three analysis techniques.
Roche buys its way out of diagnostics trouble
Roche has moved to settle its long-running legal dispute with
USA-based Igen by acquiring the firm in a deal valued at around
$1.4 billion (€1.22bn).
Amersham trims 2003 profit forecast again
Amersham trimmed its 2003 profit forecast by £40 million (€57m), or
4.1 pence per share, after reporting lower sales and pre-tax
profits for the first half of 2003.
CYP450 variant licensed for genotyping
EPIDAUROS Biotechnologie has acquired a non-exclusive licence for
the diagnostic use of one of the most important genetic variants of
the cytochrome P450 2D6 gene.